According to Johnson & Johnson there are still tons of opportunity in the immunology market, even though it´s crowded.
Jennifer Taubert, executive vice president and worldwide pharma chairman recently said at the J.P. Morgan Healthcare Conference: “We do look at immunology as being very, very attractive, and in certain areas, there’s so much unmet medical need”. “The market is still ‘dramatically underpenetrated’ by biologics.”
Einar Pontén, CEO Lipum, agrees: “Considering the remaining limitations for a range of indications the development needs to proceed. Our focus is a novel mode of action for treatment of chronic inflammations”